MétaCan
Menu
Back to cohort
Record W4413105945 · doi:10.1093/noajnl/vdaf123.081

OGCT-06 EFFICACY OF IMMUNOTHERAPY REGIMENS WITHOUT BLOOD-BRAIN BARRIER OPENING (BBBO) IN PATIENTS WITH BRAIN METASTASES (BM) FROM NON-SMALL CELL LUNG CANCER (NSCLC)

2025· article· en· W4413105945 on OpenAlexaff
Manmeet S. Ahluwalia, Nir Lipsman, Kamal Sahni, Graeme F. Woodworth, Michael McDermott, Pablo González, Hyun Ae Jung, Yazmín Odia, Rupesh Kotecha, Justin Sporrer, Federico Albrecht, D. Vile, Kingsley Nwaogu, Gaganjot Sooch, Jung-II Lee

Bibliographic record

VenueNeuro-Oncology Advances · 2025
Typearticle
Languageen
FieldMedicine
TopicBrain Metastases and Treatment
Canadian institutionsSunnybrook Hospital
Fundersnot available
KeywordsPembrolizumabMedicineBrain metastasisLung cancerChemotherapyInternal medicineOncologyMetastasisPhases of clinical researchImmunotherapyCancerRadiology

Abstract

fetched live from OpenAlex

Abstract Focused ultrasound (FUS) has emerged as a promising approach for BBBO and enhanced drug delivery of large-sized molecules like pembrolizumab, which has modest activity in patients with brain metastases (BM) from NSCLC. The BT020K and BT012 clinical trials evaluated the efficacy (at the metastasis level) and safety of pembrolizumab with/without chemotherapy and targeted BBBO using FUS or not for treating BM in patients with NSCLC. BT020K is an open-label, single-center study and BT012 is an ongoing, multicenter study with a non-randomized, safety run in phase. Overall, 12 patients were enrolled. In BT012, seven patients received pembrolizumab monotherapy without BBBO (n=17 metastases). In BT020K, five patients received pembrolizumab plus chemotherapy without BBBO (n=27 metastases). The use of gamma knife for BM without BBBO was allowed in BTO20K. High-resolution axial magnetic resonance images (MRIs) with T1-weighting and gadolinium enhancement were acquired before and after the first 6 pembrolizumab cycles, with three follow-up MRIs every 3 weeks. Metastasis volumes were estimated using the longest and perpendicular diameters; objective response rates (ORRs) were calculated based on changes from baseline in metastasis volumes. After pembrolizumab monotherapy without BBBO, metastasis volumes increased by an average of 10–31% across cycles 1–6, 10% at first follow-up and 6% at second follow-up and then decreased by 20% at final follow-up. Corresponding ORRs were 0–24% across cycles 1–6, 24% at the first two follow-ups and 53% at the final follow-up. After pembrolizumab plus chemotherapy without BBBO, metastasis volumes decreased by an average of 7–68% across cycles 1–6. Corresponding ORRs were 33–85% across cycles 1–6. These results support efforts to enhance BM response in patients treated with large-size molecules, supporting the rationale for enrolment into BBBO strategies as is being studied in BT012 and BT020K.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.339
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.008
GPT teacher head0.294
Teacher spread0.286 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueNeuro-Oncology AdvancesSame topicBrain Metastases and TreatmentFrench-language works237,207